- Home
- ZEO vs RNXT Comparison
ZEO vs RNXT Comparison
Compare ZEO & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- RNXT
- Stock Information
- Founded
- ZEO 2005
- RNXT 2012
- Country
- ZEO United States
- RNXT United States
- Employees
- ZEO N/A
- RNXT N/A
- Industry
- ZEO
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- RNXT Health Care
- Exchange
- ZEO NYSE
- RNXT Nasdaq
- Market Cap
- ZEO 31.6M
- RNXT 31.6M
- IPO Year
- ZEO N/A
- RNXT 2021
- Fundamental
- Price
- ZEO $2.57
- RNXT $1.47
- Analyst Decision
- ZEO
- RNXT Strong Buy
- Analyst Count
- ZEO 0
- RNXT 2
- Target Price
- ZEO N/A
- RNXT $6.50
- AVG Volume (30 Days)
- ZEO 1.8M
- RNXT 105.7K
- Earning Date
- ZEO 03-18-2025
- RNXT 03-31-2025
- Dividend Yield
- ZEO N/A
- RNXT N/A
- EPS Growth
- ZEO N/A
- RNXT N/A
- EPS
- ZEO N/A
- RNXT N/A
- Revenue
- ZEO $77,582,314.00
- RNXT N/A
- Revenue This Year
- ZEO N/A
- RNXT N/A
- Revenue Next Year
- ZEO N/A
- RNXT N/A
- P/E Ratio
- ZEO N/A
- RNXT N/A
- Revenue Growth
- ZEO N/A
- RNXT N/A
- 52 Week Low
- ZEO $1.05
- RNXT $0.77
- 52 Week High
- ZEO $11.60
- RNXT $1.86
- Technical
- Relative Strength Index (RSI)
- ZEO 50.64
- RNXT 51.63
- Support Level
- ZEO $2.31
- RNXT $1.31
- Resistance Level
- ZEO $2.86
- RNXT $1.69
- Average True Range (ATR)
- ZEO 0.45
- RNXT 0.11
- MACD
- ZEO -0.05
- RNXT -0.01
- Stochastic Oscillator
- ZEO 26.82
- RNXT 15.79
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy efficient equipment and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.